New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 21, 2014
07:41 EDTVRXValeant initiated with an Outperformer at CIBC
Target $160.
News For VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 3, 2015
07:14 EDTVRXSynergetics downgraded to Equal Weight from Overweight at Stephens
Subscribe for More Information
September 2, 2015
16:51 EDTVRXOn The Fly: Top stock stories for Wednesday
Subscribe for More Information
08:03 EDTVRXSynergetics to be acquired by Valeant for $6.50 per share in cash
Subscribe for More Information
08:00 EDTVRXSynergetics to be acquired by Valeant for $6.50 per share in cash
Subscribe for More Information
September 1, 2015
05:33 EDTVRXValeant, AstraZeneca to partner on brodalumab
Valeant Pharmaceuticals (VRX) announced that its affiliate has entered into a collaboration agreement with AstraZeneca (AZN) under which Valeant was granted an exclusive license to develop and commercialize brodalumab. Brodalumab is an IL-17 receptor monoclonal antibody in development for patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. Under the agreement, Valeant will hold the exclusive rights to develop and commercialize brodalumab globally, except in Japan and certain other Asian countries where rights are held by Kyowa Hakko Kirin under a prior arrangement with Amgen Inc., the originator of brodalumab. Valeant will assume all development costs associated with the regulatory approval for brodalumab. Regulatory submission in U.S. and EU for brodalumab in moderate-to-severe psoriasis is planned for Q4. Under the terms of the agreement, Valeant will make an up-front payment to AstraZeneca of $100M, as well as additional pre-launch milestones of up to $170M and further sales-related milestone payments of up to $175M following launch. After approval, AstraZeneca and Valeant will share profits.
August 25, 2015
08:05 EDTVRXValeant names D. Robert Hale to board of directors
Valeant Pharmaceuticals International announced the addition of D. Robert Hale, Partner of ValueAct Capital, to its board of directors and the resignation of Jeffrey W. Ubben, CEO and CIO of ValueAct Capital, effective as of August 19, 2015. ValueAct Capital, an investment firm based in San Francisco with over $20B under management, owns approximately 4% of the outstanding stock of Valeant, and has been a shareholder in Valeant since 2006. As a Partner and member of the investment team of ValueAct Capital, Hale has worked closely with the board and management team of Valeant since January 2011. Hale will be the fourth Partner of ValueAct Capital to serve on the Valeant Board, following Mason Morfit, Brandon Boze, and Jeff Ubben.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use